Quotient Limited Provides MosaiQ Regulatory & Commercial Update
Quotient Limited (NASDAQ:QTNT) announced its first-time attendance at the Arab Health and Medlab Middle East 2022 conference in Dubai, aiming to enhance its global presence. The company held fruitful discussions with potential distributors from the Middle East, Europe, and Asia-Pacific, indicating growing interest in its MosaiQ solution. Quotient anticipates receiving Expanded IH CE mark approval by the end of Q1 CY22, crucial for its product development. The MosaiQ platform promises significant efficiencies and cost savings in laboratory diagnostics, leveraging over 30 years of experience in transfusion diagnostics.
- First-time attendance at a major conference enhances global presence.
- Generated interest from potential distributors across various regions.
- Anticipation of Expanded IH CE mark approval by end of Q1 CY22.
- Delays or denials of regulatory approvals could impact product launch.
- Dependence on market acceptance for future growth.
- The company remains in contact with the European Notified Body and continues to anticipate approval in Q1 CY22
- First time attendance to Arab Health and Medlab Middle East 2022 in Dubai
- Generated traction on MosaiQ solution from potential distributors
JERSEY, Channel Islands, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company headquartered in Eysins, Switzerland, today announced its attendance for the first time to the Arab Health and Medlab Middle East Conference in Dubai, United Arab Emirates. Medlab Middle East 2022, a co-located event with Arab Health, hosted its 21st edition of the congress, the region’s only multi-disciplinary congress for the healthcare and laboratory industries.
Senior leaders attended the conference last week, to further advance the company’s strategic decision to broaden its global presence. They held commercial meetings with Middle East, Europe, and Asia-Pacific distributors who expressed an interest in partnering with the company. The conference provided access to new markets and customers across the regions.
“I am energized by the conversations we had with new potential distributors and look forward to partnering with them to improve clinical practice and increase laboratory efficiencies across the globe. We continue to anticipate the Expanded IH CE mark approval by the end of the quarter,” said Manuel O. Méndez, Chief Executive Officer of Quotient.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company’s MosaiQ technology to infectious disease diagnostics), current estimates of third quarter and full year fiscal 2022 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.
CONTACT: Investor Relations, ir@quotientbd.com; +41 22 545 52 26
FAQ
What is Quotient Limited's anticipated approval timeline for the Expanded IH CE mark?
What strategic event did Quotient Limited recently participate in?
How does Quotient's MosaiQ solution aim to benefit laboratories?
Which regions showed interest in Quotient Limited's products?
What are the primary risks associated with Quotient Limited's future growth?
